Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS From Major Insurance Carrier
Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS From Major Insurance Carrier
-- Reimbursement at $23,900, slightly below list price --
--赔偿额为 23,900 美元，略低于标价--
-- Represents a significant milestone toward increasing accessibility of PoNS --
--代表着提高 PON 可访问性的一个重要里程碑-
NEWTOWN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the first third-party reimbursement from a major insurance carrier for the Company's Portable Neuromodulation Stimulator (PoNS) device.
宾夕法尼亚州纽敦，2024年5月29日（GLOBE NEWSWIRE）——专注于为平衡和步态缺陷提供新型神经调节治疗方法的神经科技公司Helius Medical Technologies, Inc.（纳斯达克股票代码：HSDT）（“Helius” 或 “公司”）今天宣布，一家主要保险公司为该公司的便携式神经调节刺激器（PonS）设备提供了第一笔第三方报销。
"Securing widespread reimbursement for PoNS remains a top priority for us, and we are thrilled to announce that we've received our first third-party reimbursement for this innovative device at the list price with a 7% rebate by a major insurance carrier," said Dane Andreeff, President and Chief Executive Officer of Helius. "Following Centers for Medicare & Medicaid Services' (CMS) establishment of unique Healthcare Common Procedure Coding System codes for the PoNS mouthpiece and controller, we have been actively negotiating reimbursement with third-party payers and for patients covered by the Veterans Administration and the Department of Defense through our recent partnership with Lovell Government Services."
Helius总裁兼首席执行官Dane Andreeff表示：“确保PON的广泛报销仍然是我们的首要任务，我们很高兴地宣布，我们已经获得了该创新设备的首笔第三方报销，一家大型保险公司提供了7％的折扣。”“继医疗保险和医疗补助服务中心（CMS）为PonS的喉舌和控制者建立了独特的医疗保健通用程序编码系统代码之后，我们一直在积极与第三方付款人以及退伍军人管理局和国防部承保的患者通过最近与洛弗尔政府服务部的合作进行报销谈判。”
"We believe this is yet another important milestone in establishing the market pricing for PoNS as we continue to negotiate with other third-party payers and CMS. In addition, we are assisting several MS patients who have or are preparing to submit claims with other third-party payers and look forward to establishing reimbursement rates with those carriers as we move forward," concluded Andreeff.
“我们认为，在我们继续与其他第三方付款人和CMS进行谈判的过程中，这是确定PON市场定价的又一个重要里程碑。此外，我们正在为几名已经或准备向其他第三方付款人提交索赔的多发性硬化症患者提供援助，并期待在我们向前迈进的过程中与这些承运人确定报销率，” 安德烈夫总结道。
The reimbursed rate, net of a 7% rebate, results in pricing of $16,554 for the controller and $7,347 for the mouthpiece, exclusive of rounding.
扣除7％的折扣后，控制器的报销率为16,554美元，喉舌的定价为7,347美元，其中不包括四舍五入。